World journal of clinical oncology最新文献

{"title":"Discovery of primary lung cancer following resection of rectal cancer lung metastasis: A case report.","authors":"Fei-Yan Zhou, Fang-Hua Song, Zhen-Hao Cheng, Sen Wu","doi":"10.5306/wjco.v16.i2.99635","DOIUrl":"10.5306/wjco.v16.i2.99635","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) ranks high among the most common types of malignant tumors. The primary cause of cancer-related mortality is metastasis, with lung metastases accounting for 32.9% of all cases of metastatic CRC (MCRC). However, cases of MCRC in the lungs, which present concurrently with primary peripheral lung adenocarcinoma, are exceptionally rare.</p><p><strong>Case summary: </strong>This report describes the case of a 52-year-old female patient who, following a colonoscopy, was diagnosed with moderately differentiated adenocarcinoma based on rectal mucosal biopsy findings. A preoperative chest computed tomography scan revealed a ground-glass nodule in the right lung and a small nodule (approximately 0.6 cm in diameter) in the extramural basal segment of the left lower lobe, which suggested multiple lung metastases from rectal cancer. Subsequent treatment and follow-up led to a diagnosis of rectal cancer with left lung metastasis and peripheral adenocarcinoma of the lower lobe of the right lung.</p><p><strong>Conclusion: </strong>This case report describes the therapeutic journey of a patient with lung metastasis from rectal cancer in addition to primary peripheral adenocarcinoma, thus underscoring the critical roles of multidisciplinary collaboration, personalized treatment strategies, and comprehensive patient rehabilitation guidance.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"99635"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized treatment guided by endoscopic ultrasound-guided fine-needle aspiration for adrenocortical oncocytoma: A case report.","authors":"Han Chen, Xue Jing","doi":"10.5306/wjco.v16.i2.98223","DOIUrl":"10.5306/wjco.v16.i2.98223","url":null,"abstract":"<p><strong>Background: </strong>Adrenocortical oncocytoma is a rare, mostly benign, nonfunctional tumor that is typically detected incidentally. Its diagnosis is challenging because of the absence of distinctive imaging characteristics, necessitating pathological validation.</p><p><strong>Case summary: </strong>We present a case report of a 35-year-old woman with an adrenal mass located on the left side, where endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed after comprehensive diagnostic assessment. Our results are consistent with those of previously documented cases regarding tumor demographics and anatomical location. Given the limited number of reports on this condition, long-term follow-up is crucial to enhance our understanding of its prognosis.</p><p><strong>Conclusion: </strong>For patients with adrenocortical oncocytoma, EUS-FNA can enables collection of preoperative tissue specimens leading to suitable treatment strategies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"98223"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for overall survival in ampullary adenocarcinoma using the surveillance, epidemiology, and end results database and external validation.","authors":"Jia Yang, Zi-Yi Wang, Jing Chen, Yao Zhang, Lei Chen","doi":"10.5306/wjco.v16.i2.95910","DOIUrl":"10.5306/wjco.v16.i2.95910","url":null,"abstract":"<p><strong>Background: </strong>Ampullary adenocarcinoma is a rare malignant tumor of the gastrointestinal tract. Currently, only a few cases have been reported, resulting in limited information on survival.</p><p><strong>Aim: </strong>To develop a dynamic nomogram using internal and external validation to predict survival in patients with ampullary adenocarcinoma.</p><p><strong>Methods: </strong>Data were sourced from the surveillance, epidemiology, and end results stat database. The patients in the database were randomized in a 7:3 ratio into training and validation groups. Using Cox regression univariate and multivariate analyses in the training group, we identified independent risk factors for overall survival and cancer-specific survival to develop the nomogram. The nomogram was validated with a cohort of patients from the First Affiliated Hospital of the Army Medical University.</p><p><strong>Results: </strong>For overall and cancer-specific survival, 12 (sex, age, race, lymph node ratio, tumor size, chemotherapy, surgical modality, T stage, tumor differentiation, brain metastasis, lung metastasis, and extension) and 6 (age; surveillance, epidemiology, and end results stage; lymph node ratio; chemotherapy; surgical modality; and tumor differentiation) independent risk factors, respectively, were incorporated into the nomogram. The area under the curve values at 1, 3, and 5 years, respectively, were 0.807, 0.842, and 0.826 for overall survival and 0.816, 0.835, and 0.841 for cancer-specific survival. The internal and external validation cohorts indicated good consistency of the nomogram.</p><p><strong>Conclusion: </strong>The dynamic nomogram offers robust predictive efficacy for the overall and cancer-specific survival of ampullary adenocarcinoma.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"95910"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature.","authors":"Xuan Guo, Yan Liu, Yu-Ting Wang, Kan Liu, Hui Ding","doi":"10.5306/wjco.v16.i2.98812","DOIUrl":"10.5306/wjco.v16.i2.98812","url":null,"abstract":"<p><strong>Background: </strong>Through deeper understanding of targetable driver mutations in non-small-cell lung cancer (NSCLC) over the past years, some patients with driver mutations have benefited from the targeted molecular therapies. Although the anaplastic lymphoma kinase and BRAF mutations are not frequent subtypes in NSCLC, the availability of several targeted-drugs has been confirmed through a series of clinical trials. But little is clear about the proper strategy in rare BRAF G469A mutation, not to mention co-exhibition of anaplastic lymphoma kinase and BRAF G469A mutations, which is extremely rare in NSCLC.</p><p><strong>Case summary: </strong>We present a patient to stage IVA lung adenocarcinoma with coexisting echinoderm microtubule associated protein like-4 rearrangement and BRAF G469A mutation. She received several targeted drugs with unintended resistance and suffered from unbearable adverse events.</p><p><strong>Conclusion: </strong>Due to the rarity of co-mutations, the case not only enriches the limited literature on NSCLC harbouring BRAF G469A and echinoderm microtubule associated protein like-4 mutations, but also suggests the efficacy and safety of specific multiple-drug therapy in such patients.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"98812"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future perspectives in the management and treatment of colorectal cancer.","authors":"Sigfredo E Romero-Zoghbi, Evita Krumina, Fernando López-Campos, Felipe Couñago","doi":"10.5306/wjco.v16.i2.100807","DOIUrl":"10.5306/wjco.v16.i2.100807","url":null,"abstract":"<p><p>In this editorial, we reviewed the article by Fadlallah <i>et al</i> that was recently published in the <i>World Journal of Clinical Oncology</i>. The article provided a comprehensive and in-depth view of the management and treatment of colorectal cancer (CRC), one of the leading causes of cancer-related morbidity and mortality worldwide. The article analyzed the therapeutic modalities and their sequencing, focusing on total neoadjuvant therapy for locally advanced rectal cancer. It highlighted the role of immunotherapy in tumors with high microsatellite instability or deficient mismatch repair, addressing recent advances that have improved prognosis and therapeutic response in localized and metastatic CRC. Innovations in surgical techniques, advanced radiotherapy, and systemic agents targeting specific mutational profiles are also discussed, reflecting on how they revolutionized clinical management. Circulating tumor DNA has emerged as a promising tool for detecting minimal residual disease, prognosis, and therapeutic monitoring, solidifying its role in precision oncology. This review emphasized the importance of technological and therapeutic advancements in improving clinical outcomes and personalizing CRC treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"100807"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report.","authors":"Wei-Wu Chen, Yue-Hong Kong, Li-Yuan Zhang","doi":"10.5306/wjco.v16.i2.95642","DOIUrl":"10.5306/wjco.v16.i2.95642","url":null,"abstract":"<p><strong>Background: </strong>Bone is a major site of metastasis in nasopharyngeal carcinoma (NPC). Recently, nuclear factor kappa-beta ligand (RANKL) inhibitors have garnered attention for their ability to inhibit osteoclast formation and bone resorption, as well as their potential to modulate immune functions and thereby enhance the efficacy of programmed cell death protein 1 (PD-1) inhibitor therapy.</p><p><strong>Case summary: </strong>We present a case of a patient with NPC who developed sternal stalk metastasis and multiple bone metastases with soft tissue invasion following radical chemoradiotherapy and targeted therapy. Prior to chemotherapy, the patient experienced severe bone marrow suppression and opted out of further chemotherapy sessions. However, the patient received combination therapy, including RANKL inhibitors (denosumab) alongside PD-1, radiotherapy, and granulocyte-macrophage colony-stimulating factor (PRaG) therapy (NCT05435768), and achieved 16 months of progression-free survival and more than 35 months of overall survival, without encountering any grade 2 or higher treatment-related adverse events.</p><p><strong>Conclusion: </strong>Denosumab combined with PRaG therapy could be a new therapeutic approach for the second-line treatment in patients with bone metastases.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"95642"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cohort study on the treatment of <i>BRAF V600E</i> mutant metastatic colorectal cancer with integrated Chinese and western medicine.","authors":"Jiang-Yu Bian, Yu-Fang Feng, Wen-Ting He, Tong Zhang","doi":"10.5306/wjco.v16.i1.93670","DOIUrl":"10.5306/wjco.v16.i1.93670","url":null,"abstract":"<p><strong>Background: </strong>Patients with <i>BRAF V600E</i> mutant metastatic colorectal cancer (mCRC) have a low incidence rate, poor biological activity, suboptimal response to conventional treatments, and a poor prognosis. In the previous cohort study on mCRC conducted by our team, it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival (OS) of patients with colorectal cancer. Therefore, we further explored the survival benefits in the population with <i>BRAF V600E</i> mutant mCRC.</p><p><strong>Aim: </strong>To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of <i>BRAF V600E</i> mutant metastatic colorectal cancer.</p><p><strong>Methods: </strong>A cohort study was conducted on patients with <i>BRAF V600E</i> mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022. The patients were divided into two cohorts.</p><p><strong>Results: </strong>A total of 34 cases were included, with 23 in Chinese-Western medicine cohort (cohort A) and 11 in Western medicine cohort (cohort B). The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B, with a statistically significant difference (<i>P</i> = 0.038, hazard ratio = 0.46). The 1-3-year survival rates were 95.65% (22/23), 39.13% (9/23), and 26.09% (6/23) in cohort A, and 63.64% (7/11), 18.18% (2/11), and 9.09% (1/11) in cohort B, respectively. Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon, liver metastasis, chemotherapy, and first-line treatment subgroups (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with <i>BRAF V600E</i> mutant metastatic colorectal cancer, with more pronounced benefits observed in patients with right colon involvement, liver metastasis, combined chemotherapy, and first-line treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 1","pages":"93670"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing care for gastric cancer with overt bleeding: Is systemic therapy a valid option?","authors":"Emad Qayed","doi":"10.5306/wjco.v16.i1.100943","DOIUrl":"10.5306/wjco.v16.i1.100943","url":null,"abstract":"<p><p>Gastric cancer (GC) and gastroesophageal junction cancer (GEJC) represent a significant burden globally, with complications such as overt bleeding (OB) further exacerbating patient outcomes. A recent study by Yao <i>et al</i> evaluated the effectiveness and safety of systematic treatment in GC/GEJC patients presenting with OB. Using propensity score matching, the study balanced the comparison groups to investigate overall survival and treatment-related adverse events. The study's findings emphasize that systematic therapy can be safe and effective and contribute to the ongoing debate about the management of advanced GC/GEJC with OB, highlighting the complexities of treatment decisions in these high-risk patients.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 1","pages":"100943"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the future: Mitochondrial genes and neural networks in predicting ovarian cancer prognosis and immunotherapy response.","authors":"Zhi-Jian Tang, Yuan-Ming Pan, Wei Li, Rui-Qiong Ma, Jian-Liu Wang","doi":"10.5306/wjco.v16.i1.94813","DOIUrl":"10.5306/wjco.v16.i1.94813","url":null,"abstract":"<p><strong>Background: </strong>Mitochondrial genes are involved in tumor metabolism in ovarian cancer (OC) and affect immune cell infiltration and treatment responses.</p><p><strong>Aim: </strong>To predict prognosis and immunotherapy response in patients diagnosed with OC using mitochondrial genes and neural networks.</p><p><strong>Methods: </strong>Prognosis, immunotherapy efficacy, and next-generation sequencing data of patients with OC were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus. Mitochondrial genes were sourced from the MitoCarta3.0 database. The discovery cohort for model construction was created from 70% of the patients, whereas the remaining 30% constituted the validation cohort. Using the expression of mitochondrial genes as the predictor variable and based on neural network algorithm, the overall survival time and immunotherapy efficacy (complete or partial response) of patients were predicted.</p><p><strong>Results: </strong>In total, 375 patients with OC were included to construct the prognostic model, and 26 patients were included to construct the immune efficacy model. The average area under the receiver operating characteristic curve of the prognostic model was 0.7268 [95% confidence interval (CI): 0.7258-0.7278] in the discovery cohort and 0.6475 (95%CI: 0.6466-0.6484) in the validation cohort. The average area under the receiver operating characteristic curve of the immunotherapy efficacy model was 0.9444 (95%CI: 0.8333-1.0000) in the discovery cohort and 0.9167 (95%CI: 0.6667-1.0000) in the validation cohort.</p><p><strong>Conclusion: </strong>The application of mitochondrial genes and neural networks has the potential to predict prognosis and immunotherapy response in patients with OC, providing valuable insights into personalized treatment strategies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 1","pages":"94813"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extramedullary plasmacytoma with the uvula as first affected site: A case report.","authors":"Jing Yang, Hui Peng, Sheng-Ke Tu, Min Li, Kui Song","doi":"10.5306/wjco.v16.i1.96131","DOIUrl":"10.5306/wjco.v16.i1.96131","url":null,"abstract":"<p><strong>Background: </strong>Extramedullary plasmacytoma (EMP) represents one of the rarer forms of plasma cell malignancies, capable of impacting a variety of tissues and organs throughout the body. The majority of EMP cases are predominantly found in the head and neck region, especially within the laryngopharynx, as well as in the gastrointestinal tract. While there have been documented instances of oropharyngeal involvement in EMP cases in the academic literature, it is important to note that EMP specifically affecting the uvula is exceedingly uncommon. Furthermore, it is noteworthy that over 60% of epithelial carcinomas in the upper respiratory tract and oropharynx tend to metastasize to the cervical lymph nodes, indicating a propensity for regional spread in these types of cancers. In this context, we present a rare case of extramedullary plasmacytoma where the uvula served as the initially affected site. This case emphasizes the need for heightened awareness among clinicians regarding such unusual comorbidities, as early recognition and diagnosis can significantly influence patient management and treatment outcomes. In addition, a review of the relevant literature is included to further educate and inform healthcare professionals about this rare presentation, ultimately aiming to enhance clinical understanding and improve patient care in similar situations.</p><p><strong>Case summary: </strong>A 51-year-old man was admitted to our hospital because of a slowly enlarging neck mass. A physical examination revealed a palpable left lymph node, and magnetic resonance imaging (MRI) of the oropharynx and the neck showed a soft tissue mass in the oropharynx and enlargement of multiple lymph nodes in the neck. The soft tissue mass was diagnosed as plasmacytoma by immunohistochemical analysis. Monoclonal immunoglobulins and bone marrow biopsy showed normal results. Therefore, we diagnosed that as EMP of the uvula. After four cycles of adjuvant chemotherapy dominated by bortezomib, MRI reexamination showed a significant reduction of the mass in the oropharynx and the cervical lymph nodes. Afterwards, the λ light chain returned to normal levels. There was no evidence of evolution to multiple myeloma.</p><p><strong>Conclusion: </strong>We have reported a rare case of extramedullary plasmacytoma with the uvula as the first affected site and the relevant literature is reviewed to improve clinicians' awareness of such rare comorbidities.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 1","pages":"96131"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}